Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 31.05.15
Views: 2215

Dr Lawrence Wickerham - NRG Oncology Research Group, Pittsburgh, USA

Dr Wickerham talks to ecancertv at ASCO 2015 about final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) looking at preventing breast cancer.

Raloxifene has retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer and continued to grow closer to tamoxifen in preventing noninvasive breast cancer.

Raloxifene has also maintained a better profile with respect to uterine disease, thromboembolic events, and death.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation